/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent.
/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, has announced they have received written response from the U.S. Food and.
Arthrosi Snags $75M Series D - San Diego Business Journal sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.
The U.S. company Arthrosi Therapeutics has bagged $75 million in a Series D round to fund the clinical development of a small molecule drug for chronic gout.